B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein, together with four novel point mutations...
Guardado en:
Autores principales: | Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Mark J. Mulligan, Nathaniel R. Landau, Takuya Tada |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d27f99fff4a1464d856ab08b87f4e537 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and efficacy of RNA vaccines: State of the art
por: A. V. Blagov, et al.
Publicado: (2021) -
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021) -
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021) -
Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021) -
Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns
por: Matteo Nioi, et al.
Publicado: (2021)